Changes in Body Composition with Ritonavir‐Boosted and Unboosted Atazanavir Treatment in Combination with Lamivudine and Stavudine: A 96‐Week Randomized, Controlled Study | Zendy

Grace A. McComsey | Zendy; Anna Rightmire | Zendy; Victoria Wirtz | Zendy; Rong Yang | Zendy; Marina Mathew | Zendy; Donnie McGrath | Zendy

Open Access

Changes in Body Composition with Ritonavir‐Boosted and Unboosted Atazanavir Treatment in Combination with Lamivudine and Stavudine: A 96‐Week Randomized, Controlled Study

Author(s) -

Grace A. McComsey,

Anna Rightmire,

Victoria Wirtz,

Rong Yang,

Marina Mathew,

Donnie McGrath

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/597776

Subject(s) - atazanavir , ritonavir , stavudine , medicine , lamivudine , lipoatrophy , lopinavir/ritonavir , pharmacology , gastroenterology , virology , human immunodeficiency virus (hiv) , viral load , virus , antiretroviral therapy , hepatitis b virus

This 96-week, open-label, randomized study assessed changes in body composition in treatment-naive patients infected with human immunodeficiency virus type 1 who were treated with either atazanavir or ritonavir-boosted atazanavir, in combination with stavudine and lamivudine. Both treatment groups had similar increases in trunk fat, but patients treated with ritonavir-boosted atazanavir had a significantly lower incidence of lipoatrophy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research